Crizotinib (Xalkori) is now available through the PBS for lung cancer patients with a c-ROS proto-oncogene 1 (ROS1) gene rearrangement. From 1 January the drug is subsidised for patients with Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer. Meanwhile, other new and amended PBS listings have been recommended for several oncology ...
More PBS listings for oncology drugs
By Michael Woodhead
14 Jan 2019